Although it is likely that combining trastuzumab with other therapeutics for targeting HER2 should increase the magnitude and duration of response to trastuzumab [53,54], there are few data concerning novel strategies able to sensitize HER2-overexpressing breast cancer cells to the growth-inhibitory effects of trastuzumab [58]. This evidence concerns the gene ERBB2 and breast carcinoma.